Schram 2005.

Methods	Allocation: randomized Blinding: double‐blinded Duration: 12 months Funding: "AstraZeneca provided funding for this clinical trial (to CDAS), but had no influence on the data analyses or manuscript preparation."
Participants	Diagnosis: not reported N = 60 Age: Lisinopril group 62 ± 8 years; Candesartan group 60 ± 7 years; HCTZ group 63 ± 6 years Sex: 45% women; 55% men History: not reported Inclusion criteria: for the run‐in period were: T2DM ≥ 6 months (WHO criteria 1985); age 35‐70 years; "Caucasian ethnicity"; and urinary albumin excretion < 100 mg/24 hours. Patients with a sitting BP > 140/90 mmHg and < 190/120 mmHg after the run‐in period had an ECG. Participants were included if LVMI 490 g/m² in men or 470 g/m² in women Exclusion criteria: pregnancy or planning a pregnancy; a history of MI, angina pectoris, coronary artery bypass surgery, angioplasty, stroke, CHF, malignancy or other serious illnesses; serum creatinine > 140 mmol/L; body mass index 435 kg/m²; alcohol or drug abuse, or both; or participation in other clinical trials
Interventions	RAS inhibitor: lisinopril, candesartan; thiazide: HCTZ HCTZ 12.5 mg daily Candesartan 8 mg daily Lisinopril 10 mg daily Add‐on: consecutively, 12.5 mg HCTZ, doubling study medication; 5 mg felodipine, 50 mg metoprolol, 2 mg doxazosin, 5mg felodipine; 50 mg metoprolol, 2 mg doxazosin, 5 mg felodipine, 100 mg metoprolol, and 4 mg doxazosin
Outcomes	BP after 5 min of seated rest (mean of 3 consecutive measurements)
Notes	Participants were limited to people of "Caucasian ethnicity". The reason was not reported
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Method of sequence generation was not described
Allocation concealment (selection bias)	Unclear risk	Method of concealment was not described
Blinding of participants and personnel (performance bias) All outcomes	Low risk	Double‐blinded
Blinding of outcome assessment (detection bias) All outcomes	Unclear risk	Method of blinding was not described
Incomplete outcome data (attrition bias) All outcomes	Low risk	Missing data were unlikely to have an impact on the results of the trial
Selective reporting (reporting bias)	Low risk	Outcomes listed in the methods were all reported
Other bias	Unclear risk	Although the role of company was unlikely to have an impact on the study, no other information was found to evaluate the risk as either high or low